Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

METRONIDAZOLE

All products: general benefit

Other products in the same Health Canada class (G01A) — coverage varies; not interchangeable

  • Metronidazole + nystatin (Flagystatin): general benefit

Flagyl · DIN 01926861 · 10% · Vag Cr-App

General benefit; Health Canada lists this DIN as Cancelled post market since 2024-11-26 — choose a marketed DIN from the same-category list.Discontinued 2024-11-26 · checked 2026-09-19
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2024-11-26 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2024-11-26 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Flagyl · DIN 01926861 Manufacturer: Sanofi Aventis Pharma; listing date 1996-10-01 Health Canada: Cancelled post market since 2024-11-26 · brand FLAGYL · ATC G01AF01 METRONIDAZOLE · form Cream · route Vaginal · ingredients METRONIDAZOLE 10 % · company Sanofi-aventis canada inc · schedule Prescription
Check this DIN again · Health Canada product record

Flagyl: Formulary list price $0.2740/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2740 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=12997 · Verify on the e-Formulary ↗ (DIN 01926861)

Source record
DIN 01926861: Flagyl Raw flags: sec3=Y Item: 840416004; group id 830; item number 2022; lccId None; manufacturer id SAV Source form: Vag Cr-App; strength: 10% Recorded listing: General benefit Source prices (unrounded): $0.2740; ministry $0.2740 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=01926861 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=12997
Shortage status: not checked (no credentials)
Health Canada lists this DIN as Cancelled post market since 2024-11-26 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (84:04:16 Other Anti-Infectives) and how they are covered

Matched class: 84:04:16 Other Anti-Infectives

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: METRONIDAZOLE & NYSTATIN, SILVER SULFADIAZINE 84:04:16 Other Anti-Infectives

METRONIDAZOLE & NYSTATIN

· 2 products · General benefit · strengths: 500mg & 100000U/g, 500mg & 100000U · Vag Cr-App, Vag Sup

SILVER SULFADIAZINE

· 2 products · General benefit · strengths: 1% · Cr, Cr-50g Pk

POVIDONE - IODINE

· 2 products · Listed, not a benefit · strengths: 10% · Top Sol Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 84:04:16
Full class listing Related classes: 84:04:04 Antibiotics, 84:04:08 Fungicides, 84:04:12 Parasiticides Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1. Indications APO-METRONIDAZOLE TABLETS (Metronidazole Tablets) is indicated for: Bacterial Vaginosis Metronidazole is indicated for the treatment of bacterial vaginosis. Protozoal Infections • Trichomonal infections in men as well as in women (protozoal infection caused by Trichomonas vaginalis). • Hepatic and intestinal amebiasis. • Giardiasis. Bacterial Infections Treatment: Culture and susceptibility studies should be performed to determine the causative organisms and their susceptibility to metronidazole. Based on clinical judgment and anticipated bacteriological findings, therapy may be started while awaiting the results of these tests. However, modification of the treatment may be necessary once these results become available. In mixed aerobic and anaerobic infections, consideration should be given to the concomitant administration of an antibiotic appropriate for the treatment of the aerobic component of the infection. See 7 Warnings and Precautions, General. Metronidazole has also been used in the treatment of a small number of cases of brain or lung infections (some with abscesses) caused by anaerobic bacteria. Prophylaxis: If there are signs of infections, spe… https://pdf.hres.ca/dpd_pm/00084527.PDF PM date: 2026-04-20 Source product: APO-METRONIDAZOLE TABLETS; DIN 00545066; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.